Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
OHE at ISPOR Washington DC (1): HTA, Evidence and Pricing
9 June 2016
This is part one of two posts containing posters and presentations by members of the OHE team at ISPOR’s 21st Annual International Meeting held in Washington…
What Drives Variations in Relative Effectiveness Across Countries?
31 May 2016
This study provides an analytical framework, drawing on production function theory, to identify and quantify the determinants of relative effectiveness and sources of variation in the…
OHE Posters at HTAi: Tokyo 2016
24 May 2016
This post contains posters which were presented by members of the OHE team at the 2016 HTAi Annual Meeting held in Tokyo, Japan, 10-14 May.
OHE Presentations at HTAi: Tokyo 2016
24 May 2016
The 2016 HTAi Annual Meeting was held in Tokyo, Japan, 10-14 May 2016. The focus of the meeting was Informing Health Care Decisions with Values and…
OHE at ISPOR May 2016: Meet the Team
19 May 2016
ISPOR’s 21st Annual International Meeting is scheduled for 20-25th May 2016 in Washington DC. Several members of the OHE team will be attending and disseminating important…
OHE at ISPOR Italy Chapter – Rome: Are Wider Societal Effects Considered in Healthcare Decision-making?
17 May 2016
Martina Garau presented at the last ISPOR Italy Chapter – Rome conference on the topic of economic gains produced by health interventions.
New Publication: Opportunity Costs and Local Health Service Spending Decisions – A Qualitative Study from Wales
26 April 2016
Work by Sarah Karlsberg Schaffer (OHE), Jon Sussex (RAND Europe), Dyfrig Hughes (Bangor University) and Nancy Devlin (OHE) has recently been published in BMC Health Services…
New OHE Consulting Report on Shaping Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
18 April 2016
OHE publishes new Consulting Report on shaping the research agenda to estimate relevant cost-effectiveness thresholds for Health Technology Assessment decision making.
Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
12 April 2016
The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical…